Navigation Links
Long-term 12-month safety data on ADHD patch DAYTRANA
Date:10/26/2007

BOSTON OCTOBER 25, 2007 Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ), the global specialty biopharmaceutical company, announced that data from a 12-month study of DAYTRANATM (methylphenidate transdermal system), the Attention Deficit Hyperactivity Disorder (ADHD) patch, demonstrated that DAYTRANA provided significant ADHD tolerability and symptom control improvement in children aged 6 to 12 years. The study data was presented today at a major scientific and educational meeting of child and adolescent psychiatrists held in Boston, and is consistent with data previously presented.

In our study, children with ADHD experienced effective ADHD symptom control improvement when using DAYTRANA for 12 months, improving their ability to maintain focus and concentration in and outside of the classroom, reported investigator Frank A. Lpez, M.D., neurodevelopmental pediatrician at the Childrens Developmental Center, Winter Park, Fla. Importantly, this year-long study showed that DAYTRANA maintained a favorable safety profile throughout the study period, with adverse events consistent with previous DAYTRANA studies.

Shires DAYTRANA is the first and only patch medication approved by the U.S. Food and Drug Administration (FDA) to treat the symptoms of ADHD in children aged 6 to 12 years. The study results demonstrate that adverse events associated with DAYTRANA were similar to other methylphenidate products. The most common adverse events reported in this study were decreased appetite, headache, upper respiratory tract infection, cough, fever, and decreased weight. When worn for the recommended nine hours, efficacy has been demonstrated from the first time point measured (two hours) through the 12-hour time point. Because DAYTRANA is a patch, physicians may recommend that patients shorten the wear time if shorter duration of effect is desired or to help manage the potential for late-day side effects, such as lack of appetite or difficulty sleeping.

Lpez added, DAYTRANAs novel patch delivery system offers physicians and parents of children with ADHD a convenient, non-oral option to individualize ADHD treatment to meet their childrens changing schedules.

While this study evaluated the safety and effectiveness of DAYTRANA for up to 12 months, DAYTRANA has not been studied versus placebo for longer than 7 weeks. Physicians, who prescribe DAYTRANA for long-term use, should periodically re-evaluate patients to assess the usefulness of DAYTRANA for the individual patient.

The study was supported by funding from Shire.


'/>"/>

Contact: Jennifer Anello
212-601-8132
Porter Novelli
Source:Eurekalert

Related medicine news :

1. Pancreatitis: Minimially Invasive Procedure Offers Long-Term Pain Relief
2. Long-Term Survival can be Predicted by a Simple Lung Test
3. Small lumps in breast if not treated may cause long-term harm
4. Lung Therapy Found To Have Long-Term Side Effects
5. Long-Term Benefits Of Statins Questioned
6. Long-term use of calcium supplements to prevent colon cancer
7. Survivors of childhood cancer may have long-term health problems
8. Long-term Care Should Be A Planned Affair
9. Pfizer vouches safety of long-term inhaled insulin.
10. Clue to Link Between Obesity and Long-Term Memory Discovered
11. Drug Regulators Need To Think In Long-Term, Say Charities
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2017)... ... May 24, 2017 , ... Drs. Nicholas Rallis ... have now spent 10 years as clinical instructors for the reputable Full Mouth ... Dentistry. Through the program, private practitioners receive cutting-edge clinical training and learn how ...
(Date:5/24/2017)... ... ... Myers Jackson is well known for auctioning homes that people move and ... the planet. The luxury home market is alive and well and there are mansions ... of “11 Spyglass Hill Auction will enlighten you on the dynamics of how to ...
(Date:5/24/2017)... , ... May 24, 2017 , ... ... of ExtraHop to its solutions portfolio. ExtraHop delivers an analytics-first approach, layered with ... every IT system, from the datacenter to the cloud to the edge. Through ...
(Date:5/24/2017)... ... May 24, 2017 , ... The CFOs included ... and health systems in the nation and help their organizations navigate the challenges ... and been instrumental in developing successful hospital and health system strategy. , Becker's ...
(Date:5/23/2017)... ... May 23, 2017 , ... MDLand International (MDLand), a ... today that its iClinic V12.2 solution has achieved approval from National Center for ... PCMH 2017 standards which emphasize team-based care with a significant focus on the ...
Breaking Medicine News(10 mins):
(Date:5/8/2017)... Mich. , May 8, 2017  Diplomat Pharmacy, ... WRB Communications, Inc. ("WRB"), a health care service ... . WRB specializes in relationship management programs ... WRB will join ... Diplomat,s commercialization support services for manufacturers, biotech firms, and ...
(Date:5/6/2017)... , May 5, 2017  Hill-Rom Holdings, Inc. (NYSE: ... approximately 100,000 square feet to its Welch Allyn campus. ... its commitment to bring more than 100 new jobs ... Welch Allyn has maintained a significant presence for more ... these new positions, a large portion of which will ...
(Date:5/4/2017)... , May 4, 2017 Clarius ... its wireless, handheld ultrasound scanners this week at ... Scientific Meeting (ACOG) in San Diego, ... "Clarius is the perfect tool for ... and heart rate, and evaluate pregnancy-related complications like ...
Breaking Medicine Technology: